BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up - Here's Why

Key Points

• BLSM shares gapped higher, opening at $20.31 versus a prior close of $19.38, amid increased analyst coverage and a bullish consensus rating.
• Leerink, HC Wainwright, Guggenheim, Lifesci Capital and JPMorgan initiated coverage with positive ratings and price targets ranging from $28 to $36; the consensus target is $32.20.
• Despite expectations that losses will narrow, BlossomHill remains unprofitable, with projected negative EPS through fiscal 2027. Insiders bought approximately 1.57 million shares worth $25.2 million in the past quarter, while upcoming conference presentations could raise investor visibility.

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $19.38, but opened at $20.31. BlossomHill Therapeutics shares last traded at $20.05, with a volume of 15,940 shares traded.

BlossomHill Therapeutics News Summary

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $36 price target, while HC Wainwright began coverage with a Buy rating and a $35 target. These targets imply substantial potential upside and provide new institutional validation for BlossomHill’s development strategy. BlossomHill Therapeutics analyst coverage
• Positive Sentiment: Guggenheim also initiated coverage with a Buy rating and a $30 price target, adding to the consensus bullish view. Lifesci Capital separately began coverage with an Outperform rating and a $32 target. Guggenheim initiates coverage
• Positive Sentiment: HC Wainwright projects that quarterly losses will narrow from $0.92 per share in the third quarter of 2026 to $0.69 per share by the third quarter of 2027. Its $35 price target and Buy rating reinforce the optimistic outlook. HC Wainwright earnings estimates
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events may increase visibility for its cancer-focused small-molecule programs and create opportunities for investor engagement. BlossomHill conference presentation announcement
• Neutral Sentiment: Lifesci Capital and JPMorgan Chase also initiated coverage, expanding analyst attention around BLSM, although the supplied reports did not provide their ratings or price targets.
• Negative Sentiment: BlossomHill remains forecast to report losses, including estimated fiscal 2026 EPS of negative $3.71 and fiscal 2027 EPS of negative $2.99. Continued losses and the need to fund clinical development remain risks despite the expected improvement in earnings.

Analyst Upgrades and Downgrades

BLSM has been the topic of several recent analyst reports. Wall Street Zen raised shares of BlossomHill Therapeutics to a "hold" rating in a research report on Saturday, August 15th. Lifesci Capital assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $32.00 target price for the company. Leerink Partners assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $36.00 price target for the company. Guggenheim initiated coverage on BlossomHill Therapeutics in a research report on Tuesday. They set a "buy" rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a report on Tuesday. They set an "overweight" rating and a $28.00 price target on the stock. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $32.20.

BlossomHill Therapeutics Stock Performance

Insiders Place Their Bets

In related news, Director John P. Schmid bought 6,000 shares of the company's stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the purchase, the director directly owned 6,000 shares in the company, valued at $96,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Carl L. Gordon bought 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares in the company, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source